Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of FTY720 in Patients With Relapsing Multiple Sclerosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Core Study~Inclusion Criteria:~* Diagnosis of relapsing multiple Sclerosis (MS)~* Patients with at least two documented relapses in the previous 2 years or one documented relapse in the last year~* Patients with an Expanded Disability Status Scale (EDSS) score of 0-6~Extension Study~* A positive Gd-enhanced MRI scan at screening (in case the first MRI scan obtained at screening was negative, a second scan could have been obtained 1 month later)~* Neurologically stable with no evidence of relapse within 30 days prior to randomization,or during the Screening and Baseline periods.~* Female patients either post-menopausal, surgically incapable of bearing children, or practicing an acceptable method of birth control. Females of childbearing potential with a negative pregnancy test at baseline prior to entry into the treatment period.~Exclusion Criteria:~Core Study~* Patients with other chronic disease of the immune system, malignancies, pulmonary or heart disease, etc~* Pregnant or nursing women~Extension Study~* Patients who had permanently discontinued study drug prior to the Month 6 visit of the core study~* Patients with diabetes mellitus (to reduce the risk of ME), and therefore ongoing patients with diabetes mellitus or who developed diabetes mellitus were discontinued from the study)~Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Fingolimod (FTY720) 1.25 mg/day (Type: EXPERIMENTAL): Core study: patients received fingolimod 1.25 mg, once daily for 6 months. Extension: In dose -blind period and open label, fingolimod 1.25 mg once daily for 9-18 months (6 months to 24 months). Later, all patients converted to fingolimod 0.5 mg, once daily for rest of the study participation.
- Placebo/Fingolimod (FTY720) (Type: PLACEBO_COMPARATOR): Core study: patients received placebo, once daily for 6 months. Extension: In dose-blind period patients were re-randomized into either fingolimod 1.25 mg or 5.0 mg once per day for 6-15 months. In open-label period patients received fingolimod 1.25 mg once per day for 15 to 24 months. Later, all patients converted to fingolimod 0.5 mg, once daily for rest of the study participation.
- Fingolimod (FTY720) 5.0 mg/day (Type: EXPERIMENTAL): Core study: patients received fingolimod 5.0 mg, once daily for 6 months. Extension: In dose-blind period fingolimod 5.0 mg once daily for 6-15 months. For open-label phase 15 to 24 months 1.25mg once daily. Later, all patients converted to fingolimod 0.5 mg, once daily for rest of the study participation.

Based on this trial design, predict the completion outcome and termination type (if applicable).